G0333 HCPCS Level II code: Pharmacy dispensing fee for inhalation drug(s); initial 30-day supply as a beneficiary

G0333 is the HCPCS code for “Pharmacy dispensing fee for inhalation drug(s); initial 30-day supply as a beneficiary” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

G0333

Pharmacy dispensing fee for inhalation drug(s); initial 30-day supply as a beneficiary

Short description: Dispense fee initial 30 day

HCPCS · United States

Notes for G0333

As CMS prints them, with any note G0333 takes from the headings above it.

Note

  • CMS processing note 0121: SECTION 303(e)(2) OF THE MMA IMPLEMENTS A SUPPLYING FEE FOR IMMUNOSUPPRESSIVE DRUGS, ORAL ANTI-CANCER CHEMOTHERAPEUTIC DRUGS, AND ANTI-EMETIC DRUGS USED AS PART OF AN ANTI-CANCER CHEMOTHERAPEUTIC REGIMEN.

Medicare details

The indicators CMS publishes with G0333 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Special coverage instructions apply
Medicare pricing
DMEPOS fee schedule – Carrier priced (e.g., not otherwise classified, individual determination, carrier discretion, gap-filled amounts)
Type of service
Other medical items or services
BETOS category
Other DME
Added
Jan 1, 2006

Where G0333 sits

  1. 1G codesProcedures and professional services
  2. 2Active code G0333Pharmacy dispensing fee for inhalation drug(s); initial 30-day supply as a beneficiary

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code G0333 mean?

G0333 is the HCPCS code for “Pharmacy dispensing fee for inhalation drug(s); initial 30-day supply as a beneficiary” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover G0333?

CMS lists G0333’s Medicare coverage as “Special coverage instructions apply” and its pricing as “DMEPOS fee schedule – Carrier priced (e.g., not otherwise classified, individual determination, carrier discretion, gap-filled amounts)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.

G0322The collection of physiologic data digitally stored and/or transmitted by the patient to the home health agency (i.e., remote patient monitoring)G0323Care management services for behavioral health conditions, at least 20 minutes of clinical psychologist, clinical social worker, mental health counselor, or marriage and family…G0327Colorectal cancer screening; blood-based biomarkerG0328Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneousG0329Electromagnetic therapy, to one or more areas for chronic stage iii and stage iv pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers not demonstrating…G0330Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care)…G0337Hospice evaluation and counseling services, pre-electionG0339Image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatmentG0340Image-guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per…G0341Percutaneous islet cell transplant, includes portal vein catheterization and infusionG0342Laparoscopy for islet cell transplant, includes portal vein catheterization and infusionG0343Laparotomy for islet cell transplant, includes portal vein catheterization and infusion